EMA grants orphan drug designations to Alnylam’s ALN-AT3 for haemophilia treatment

Biopharmaceutical company Alnylam Pharmaceuticals has received orphan drug designations for ALN-AT3 from the European Medicines Agency (EMA) Committee to treat haemophilia A and B.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news